Exagen (NASDAQ:XGN - Get Free Report) had its price objective hoisted by research analysts at Canaccord Genuity Group from $7.00 to $8.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the stock. Canaccord Genuity Group's target price indicates a potential upside of 33.11% from the company's current price.
Other research analysts have also issued reports about the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $8.00 price target on shares of Exagen in a report on Monday, January 13th. BTIG Research restated a "buy" rating on shares of Exagen in a research report on Wednesday, May 7th. Finally, William Blair restated an "outperform" rating on shares of Exagen in a research report on Wednesday, March 12th.
Read Our Latest Report on XGN
Exagen Stock Performance
XGN traded up $0.27 on Tuesday, hitting $6.01. The company had a trading volume of 248,650 shares, compared to its average volume of 109,706. The company's fifty day moving average price is $4.81 and its 200 day moving average price is $4.21. Exagen has a 1-year low of $1.71 and a 1-year high of $7.20. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05. The stock has a market cap of $128.01 million, a price-to-earnings ratio of -6.39 and a beta of 1.50.
Exagen (NASDAQ:XGN - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, hitting the consensus estimate of ($0.20). Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. The firm had revenue of $15.50 million during the quarter, compared to analyst estimates of $14.55 million. During the same period in the previous year, the company earned ($0.19) EPS. Equities analysts predict that Exagen will post -0.88 earnings per share for the current fiscal year.
Institutional Trading of Exagen
A number of institutional investors and hedge funds have recently modified their holdings of XGN. Toronto Dominion Bank bought a new stake in Exagen in the fourth quarter valued at $3,655,000. Driehaus Capital Management LLC bought a new stake in Exagen in the fourth quarter valued at $1,716,000. Marshall Wace LLP bought a new stake in Exagen in the fourth quarter valued at $66,000. Kennedy Capital Management LLC grew its position in Exagen by 8.8% in the fourth quarter. Kennedy Capital Management LLC now owns 184,473 shares of the company's stock valued at $756,000 after acquiring an additional 14,920 shares during the period. Finally, Palumbo Wealth Management LLC grew its position in Exagen by 14.4% in the first quarter. Palumbo Wealth Management LLC now owns 99,205 shares of the company's stock valued at $356,000 after acquiring an additional 12,501 shares during the period. 75.25% of the stock is currently owned by institutional investors.
Exagen Company Profile
(
Get Free Report)
Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Featured Stories
Before you consider Exagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exagen wasn't on the list.
While Exagen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
